Xuan Zhang Selected Research

Proteolysis Targeting Chimera

5/2024	An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
1/2023	Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.
1/2022	Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
11/2021	Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
1/2021	Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells.
8/2020	Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines.
1/2020	DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
1/2020	PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
1/2020	PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors.
1/2020	Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xuan Zhang Research Topics

Disease

264	Neoplasms (Cancer) 05/2024 - 06/2004
65	Inflammation (Inflammations) 05/2024 - 05/2010
48	Infections 12/2024 - 06/2003
29	Hepatocellular Carcinoma (Hepatoma) 11/2023 - 01/2009
29	Breast Neoplasms (Breast Cancer) 11/2023 - 10/2006
26	Fibrosis (Cirrhosis) 05/2024 - 05/2008
26	Rheumatoid Arthritis 01/2024 - 11/2010
23	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2023 - 06/2003
23	Neoplasm Metastasis (Metastasis) 08/2023 - 10/2006
23	Schizophrenia (Dementia Praecox) 07/2023 - 01/2004
20	Hypoxia (Hypoxemia) 03/2024 - 06/2004
18	Stomach Neoplasms (Stomach Cancer) 05/2024 - 05/2012
18	Colorectal Neoplasms (Colorectal Cancer) 12/2023 - 01/2016
18	Glioma (Gliomas) 11/2023 - 05/2009
17	Melanoma (Melanoma, Malignant) 05/2024 - 08/2005
17	Autoimmune Diseases (Autoimmune Disease) 12/2023 - 01/2004
16	Carcinogenesis 03/2024 - 01/2016
15	Lung Neoplasms (Lung Cancer) 02/2024 - 05/2012
14	Virus Diseases (Viral Diseases) 05/2024 - 11/2014
14	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 07/2008
14	Pain (Aches) 01/2024 - 01/2004
13	COVID-19 01/2024 - 01/2020
13	Body Weight (Weight, Body) 01/2023 - 04/2009
12	Hypertension (High Blood Pressure) 04/2024 - 02/2005
12	Obesity 04/2023 - 04/2009
12	Atherosclerosis 01/2023 - 05/2009
11	Hemorrhage 05/2024 - 10/2009
11	Heart Failure 03/2024 - 02/2019
11	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 02/2016
11	Hepatitis B 05/2023 - 07/2008
11	Carcinoma (Carcinomatosis) 01/2023 - 06/2010
10	Insulin Resistance 08/2023 - 04/2015
10	Immunoglobulin G4-Related Disease 01/2022 - 11/2015
9	Pancreatic Neoplasms (Pancreatic Cancer) 06/2022 - 08/2008
9	Experimental Melanoma 10/2021 - 06/2005
9	Ovarian Neoplasms (Ovarian Cancer) 11/2020 - 08/2008
8	Colonic Neoplasms (Colon Cancer) 04/2024 - 08/2014
8	Necrosis 02/2024 - 09/2017
8	Wounds and Injuries (Trauma) 11/2023 - 02/2013
8	Hyperalgesia 01/2023 - 12/2003
8	Disease Progression 01/2023 - 09/2011
8	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 02/2010
8	Thrombocytopenia (Thrombopenia) 01/2021 - 09/2011

Drug/Important Bio-Agent (IBA)

102	Proteins (Proteins, Gene)FDA Link 05/2024 - 04/2008
54	Biomarkers (Surrogate Marker)IBA 05/2024 - 01/2011
41	Peptides (Polypeptides)IBA 05/2024 - 06/2004
28	MicroRNAs (MicroRNA)IBA 01/2024 - 01/2011
28	Liposomes (Liposome)IBA 12/2021 - 08/2005
25	Messenger RNA (mRNA)IBA 01/2024 - 02/2004
25	AntibodiesIBA 01/2023 - 04/2007
23	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2024 - 10/2005
22	Immunoglobulin G (IgG)IBA 01/2023 - 01/2009
21	LigandsIBA 03/2024 - 06/2009
21	AntigensIBA 01/2024 - 05/2010
21	LipidsIBA 12/2023 - 04/2009
20	CytokinesIBA 02/2024 - 06/2015
19	Long Noncoding RNAIBA 04/2024 - 01/2016
18	Paclitaxel (Taxol)FDA LinkGeneric 12/2024 - 06/2010
18	EnzymesIBA 05/2024 - 07/2008
18	RNA (Ribonucleic Acid)IBA 01/2024 - 12/2015
18	AutoantibodiesIBA 10/2022 - 04/2005
17	MicellesIBA 01/2024 - 04/2009
16	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 12/2005
15	AntioxidantsIBA 05/2024 - 04/2015
14	GlucocorticoidsIBA 04/2024 - 09/2011
13	Therapeutic UsesIBA 04/2024 - 06/2005
13	Phosphotransferases (Kinase)IBA 02/2024 - 05/2012
12	Interleukin-6 (Interleukin 6)IBA 12/2024 - 04/2016
12	IntegrinsIBA 05/2024 - 08/2005
11	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 07/2010
10	Proteolysis Targeting ChimeraIBA 05/2024 - 01/2020
10	LipopolysaccharidesIBA 11/2023 - 02/2015
10	Caspase 3 (Caspase-3)IBA 11/2022 - 08/2008
9	snake venom protein C activatorIBA 05/2024 - 12/2019
9	Estrogens (Estrogen)FDA Link 01/2023 - 02/2004
9	VaccinesIBA 01/2022 - 02/2010
9	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 09/2011
8	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2020
8	Circular RNAIBA 02/2024 - 01/2017
8	Hormones (Hormone)IBA 01/2024 - 10/2012
8	Indicators and Reagents (Reagents)IBA 06/2023 - 04/2010
8	Angiotensin IIIBA 06/2023 - 07/2008
8	Small Interfering RNA (siRNA)IBA 01/2023 - 10/2006
8	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2023 - 09/2011
8	CollagenIBA 07/2022 - 09/2013
8	Cisplatin (Platino)FDA LinkGeneric 11/2020 - 11/2014
7	Anti-Bacterial Agents (Antibiotics)IBA 12/2024 - 04/2006
7	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2024 - 09/2016
7	GoldIBA 05/2024 - 02/2011
7	SteroidsIBA 04/2024 - 02/2004
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2024 - 02/2011

Therapy/Procedure

135	Therapeutics 12/2024 - 06/2003
29	Drug Therapy (Chemotherapy) 05/2024 - 03/2009
23	Immunotherapy 05/2024 - 07/2009
11	Chinese Traditional Medicine (Traditional Chinese Medicine) 03/2024 - 07/2010
10	Radiotherapy 02/2024 - 01/2013
10	Transplantation 09/2023 - 06/2007
9	Aftercare (After-Treatment) 01/2022 - 01/2011
8	Ligation 05/2024 - 08/2016
8	Lasers (Laser) 01/2024 - 03/2010